Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21208841)

  • 1. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.
    Asghar U; Hawkes E; Cunningham D
    Clin Colorectal Cancer; 2010 Dec; 9(5):274-81. PubMed ID: 21208841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.
    Berg M; Soreide K
    Discov Med; 2012 Sep; 14(76):207-14. PubMed ID: 23021375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
    Custodio A; Feliu J
    Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis.
    Xu Q; Xu AT; Zhu MM; Tong JL; Xu XT; Ran ZH
    J Dig Dis; 2013 Aug; 14(8):409-16. PubMed ID: 23615046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of molecular biomarkers in individualized treatment of colorectal cancer.
    De Mattos-Arruda L; Dienstmann R; Tabernero J
    Clin Colorectal Cancer; 2011 Dec; 10(4):279-89. PubMed ID: 21729679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer.
    Hendifar A; Tan CR; Annamalai A; Tuli R
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1051-61. PubMed ID: 24898788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular predictors of response to chemotherapy in colorectal cancer.
    Dienstmann R; Vilar E; Tabernero J
    Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.
    Okada Y; Miyamoto H; Goji T; Takayama T
    Digestion; 2014; 89(1):18-23. PubMed ID: 24458108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biomarker for chemotherapy in patients with colorectal cancer].
    Matsusaka S
    Gan To Kagaku Ryoho; 2009 Jan; 36(1):11-4. PubMed ID: 19151559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
    Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
    Bouché O; Beretta GD; Alfonso PG; Geissler M
    Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.
    Troiani T; Zappavigna S; Martinelli E; Addeo SR; Stiuso P; Ciardiello F; Caraglia M
    Expert Opin Biol Ther; 2013 Feb; 13(2):241-55. PubMed ID: 23281932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Perspective of personalized (precise) cancer therapy based on predictive biomarkers].
    Osera S; Yoshino T
    Nihon Rinsho; 2014 Jan; 72(1):29-34. PubMed ID: 24597345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work.
    Stintzing S; Stremitzer S; Sebio A; Lenz HJ
    Hematol Oncol Clin North Am; 2015 Feb; 29(1):43-60. PubMed ID: 25475572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation.
    Giampieri R; Scartozzi M; Del Prete M; Maccaroni E; Bittoni A; Faloppi L; Bianconi M; Cecchini L; Cascinu S
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):272-83. PubMed ID: 23806981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action.
    Heinemann V; Douillard JY; Ducreux M; Peeters M
    Cancer Treat Rev; 2013 Oct; 39(6):592-601. PubMed ID: 23375249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
    Cervera P; Fléjou JF
    Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
    De Mattia E; Cecchin E; Toffoli G
    Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice.
    Maurel J; Postigo A
    Curr Cancer Drug Targets; 2015; 15(8):703-15. PubMed ID: 26452385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting.
    Rolfo C; Russo A; Santini D; Bronte G; Peeters M
    Expert Opin Ther Targets; 2013 Aug; 17(8):869-71. PubMed ID: 23848525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.